Valuation: BioGaia AB

Market Cap 11.48B 1.15B 1.02B 955M 868M 1.63B 111B 1.65B 4.49B 56.39B 4.3B 4.21B 181B P/E 2026 *
29.9x
P/E 2027 * 23.9x
Enterprise Value 10.82B 1.08B 965M 900M 818M 1.54B 104B 1.55B 4.23B 53.12B 4.05B 3.97B 171B EV / Sales 2026 *
6.5x
EV / Sales 2027 * 5.74x
Free-Float
80.82%
Yield 2026 *
3.61%
Yield 2027 * 3.86%
1 day+0.81%
3 months+13.18%
6 months+13.18%
Current year+13.18%
Current year 9.64
Extreme 9.64
12.45
1 year 9.64
Extreme 9.64
12.45
3 years 8.79
Extreme 8.79
12.45
5 years 7.5
Extreme 7.5
17.14
10 years 0
Extreme 0
17.14
Manager TitleAgeSince
Chief Executive Officer 60 2023-09-29
Director of Finance/CFO 59 2019-11-04
Chief Operating Officer 49 2020-12-31
Director TitleAgeSince
Chairman 77 2002-12-31
Director/Board Member 46 2014-12-31
Director/Board Member 40 2019-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.81%-.--% - - 1.16B
+2.70%+0.35%+40.67%+110.31% 1,032B
+1.44%-3.41%+37.36%+63.95% 614B
+1.75%+3.07%+17.89%+83.05% 471B
+0.60%-4.35%+60.80%+37.46% 350B
+2.92%+3.06%+24.83%+45.10% 337B
+2.42%-0.74%+13.44%+35.80% 268B
+1.86%-0.81%-4.69%+12.20% 246B
+2.60%-2.49%+40.45%+54.44% 218B
+1.82%-2.93%+29.29%+96.48% 179B
Average +1.62%-3.39%+28.89%+59.87% 412.76B
Weighted average by Cap. +1.88%-3.18%+32.16%+70.59%

Financials

2026 *2027 *
Net sales 1.66B 166M 149M 139M 126M 237M 16.08B 239M 650M 8.18B 624M 610M 26.29B 1.89B 188M 168M 157M 143M 268M 18.21B 270M 737M 9.26B 707M 692M 29.78B
Net income 385M 38.43M 34.34M 32.04M 29.1M 54.81M 3.72B 55.22M 150M 1.89B 144M 141M 6.08B 480M 47.92M 42.81M 39.94M 36.28M 68.33M 4.64B 68.84M 188M 2.36B 180M 176M 7.58B
Net Debt -666M -66.43M -59.36M -55.38M -50.3M -94.74M -6.43B -95.45M -260M -3.27B -249M -244M -10.51B -648M -64.64M -57.75M -53.88M -48.94M -92.18M -6.25B -92.86M -253M -3.18B -243M -237M -10.22B
Projected Income Statement - Annual - BioGaia AB
Logo BioGaia AB
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.
Employees
251
Date Price Change Volume
26-10-05 US$0.000000 - 92
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - BioGaia AB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
113.50SEK
Average target price
155.50SEK
Spread / Average Target
+37.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BioGaia AB